Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $124,436.70 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Ramy Riad Ahmed Ibrahim sold 7,277 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $124,436.70. Following the completion of the transaction, the insider owned 102,588 shares in the company, valued at approximately $1,754,254.80. This represents a 6.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company has a 50 day moving average price of $16.57 and a 200 day moving average price of $17.14. The stock has a market capitalization of $56.53 billion, a P/E ratio of 51.89 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $6.90 billion for the quarter. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 0.32 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $998,000. Quantinno Capital Management LP boosted its stake in shares of Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after buying an additional 219,999 shares during the period. Bleakley Financial Group LLC grew its position in shares of Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after buying an additional 68,844 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Takeda Pharmaceutical during the second quarter worth about $351,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TAK shares. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.